ACE-011
by Alyssa Liguori
Published: Dec 26, 2009 5:24 pm
Published: Dec 26, 2009 5:24 pm
| Brand Name: | |
| Generic Name: | |
| Code Name: | ACE-011 |
| Company: | Celgene and Acceleron Pharma |
| FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined two different genes, each of which typically code for separate proteins. By fusing the genes, a new, unique protein is created with certain functions from both of the original proteins. This fusion protein, ACE-011, inhibits bone loss and promotes bone formation.
Clinical Trials:
For a list of clinical trials studying ACE-011 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for ACE-011: http://www.acceleronpharma.com.
Updated December 26, 2009
Related Articles:
- New Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma Therapeutic Vaccines
- Immune System Cells Protect Myeloma Cancer Cells, Study Finds
- Recent Advances In The Treatment Of Myeloma Bone Disease
- Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
- New Advances In Myeloma Vaccines – Part 4: Ongoing Research
Leave a comment